Bromocriptine is a dopamine D2 receptor agonist used for the treatment of galactorrhea due to hyperprolactinemia and other prolactin-related conditions, ... Identification · Pharmacology · Interactions · Products

Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat ...

Visit DrugBank.com for detailed drug and target data for your pharmaceutical research. ... Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets.

Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control.

Bromocriptine completed Phase 3 trials for Parkinson's Disease (PD) treatment. Back to Bromocriptine. Stay up-to-date with the latest from DrugBank!

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease.

QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes. Bromocriptine (DB01200) · Insulin human (DB00030) ...

Bromocriptine Completed Phase 3 Trials for Type 2 Diabetes Mellitus Treatment ; NCT00377676, Safety and Tolerability Study of Cycloset in Treatment of Type 2 ...

Bromocriptine Completed Phase 1 Trials for Type 2 Diabetes Mellitus Treatment ; NCT02078440. Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and ...

Bromocriptine is a promising therapy for diabetes patients and demonstrates modest improvements in glycemic control. DrugBank Data that Cites this Article. Drug ...